Jakovljevic Mihajlo, Matter-Walstra Klazien, Sugahara Takuma, Sharma Tarang, Reshetnikov Vladimir, Merrick Joav, Yamada Tetsuji, Youngkong Sitaporn, Rovira Joan
1Department of Global Health Economics and Policy, University of Kragujevac, Kragujevac, Serbia.
2Institute of Comparative Economic Studies, Faculty of Economics, Hosei University Tokyo, Tokyo, Japan.
Cost Eff Resour Alloc. 2020 Apr 2;18:15. doi: 10.1186/s12962-020-00210-2. eCollection 2020.
Since its inception in 2003, journal has come a long way over the past 18 years. Possibly much longer than many of its contemporaries in the blossoming science of health economics might have anticipated. Today, entering 2020 it celebrates the Age of Maturity. We believe that in the third decade of XXI century the interdisciplinary science of health economics, will rejuvenate and come back to us younger than ever from its early historical roots almost a century ago. The spreading of economic globalization in several distinctive ways, either led by multinational business corporations or newly emerged Asian leadership, or both, is likely to make challenges for contemporary health systems far more serious. The fourth industrial revolution (cyber physical systems and artificial intelligence technology) and accelerated innovation in the field of E-Health and digital health, will probably change the workflow in medical and health care, and inevitably transform the labour market in the upcoming decades. So, let us be up to the task. Let us provide academic centres, industry-sponsored pharmaceutical and medical device innovation hubs, and governing authorities alike, with a powerful forum for debate on cost-effective resource allocation in the years to come.
自2003年创刊以来,该期刊在过去18年里取得了长足的发展。其发展历程可能比许多同期在蓬勃发展的健康经济学领域的同行所预期的要长得多。如今,进入2020年,它迎来了成熟期。我们相信,在21世纪的第三个十年,健康经济学这一跨学科科学将重焕生机,从近一个世纪前的早期历史根源回归,且比以往任何时候都更具活力。经济全球化以多种独特方式蔓延,无论是由跨国商业公司引领,还是新兴的亚洲领导力引领,亦或是两者共同引领,都可能使当代卫生系统面临的挑战更加严峻。第四次工业革命(网络物理系统和人工智能技术)以及电子健康和数字健康领域的加速创新,可能会改变医疗保健的工作流程,并在未来几十年不可避免地改变劳动力市场。所以,让我们肩负起这项任务。让我们为学术中心、行业赞助的制药和医疗器械创新中心以及管理当局提供一个强大的论坛,以便在未来几年就具有成本效益的资源分配展开辩论。